Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Inventory: 2011-2025

Historic Change in Inventory for Myriad Genetics (MYGN) over the last 13 years, with Sep 2025 value amounting to $2.9 million.

  • Myriad Genetics' Change in Inventory was N/A to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year change of. This contributed to the annual value of $6.2 million for FY2024, which is 244.44% up from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Change in Inventory is $2.9 million, which was up 866.67% from $300,000 recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Change in Inventory ranged from a high of $4.3 million in Q3 2022 and a low of -$3.2 million during Q4 2021.
  • Its 3-year average for Change in Inventory is $1.2 million, with a median of $1.5 million in 2023.
  • Its Change in Inventory has fluctuated over the past 5 years, first plummeted by 192.31% in 2021, then surged by 750.00% in 2023.
  • Myriad Genetics' Change in Inventory (Quarterly) stood at -$3.2 million in 2021, then surged by 53.12% to -$1.5 million in 2022, then tumbled by 113.33% to -$3.2 million in 2023, then spiked by 140.62% to $1.3 million in 2024, then plummeted by 90.32% to $2.9 million in 2025.
  • Its Change in Inventory was $2.9 million in Q3 2025, compared to $300,000 in Q2 2025 and $900,000 in Q1 2025.